Strategic funding Orasis has secured a substantial funding round including a $78M Series D with co-led investments from Arboretum Ventures and Johnson & Johnson Innovation, plus $15M structured capital. This indicates strong investor validation and capacity to scale commercial activities, suggesting opportunities for channel partners, contract manufacturing, and large-scale distribution collaborations.

Product launch momentum Qlosi is progressing toward widespread US prescribing availability via BlinkRx and Medvantx with in-office dispensing where permitted, and recent executive hires focused on sales and operations to support the commercial launch. This creates upside for distributors, specialty pharmacies, and ophthalmic clinics seeking ready-to-market presbyopia solutions.

Access expansion First Fill Free program through BlinkRx and in-office dispensing initiatives expand patient access and reduce initial barriers to adoption. This suggests sales opportunities with payer-facing teams, pharmacy benefit managers, and patient-access programs that can be bundled with physician education and patient support services.

Quality and scale readiness New leadership in quality and operations alongside a dedicated VP of sales signals readiness for large-scale commercialization, regulatory compliance, and high-volume distribution. Opportunities exist for contract manufacturing optimization, quality systems partnerships, and regional field deployment strategies.

Clinical and market demand Presbyopia focus positions Orasis at a large, growing ocular care segment with early-stage Phase II efforts for CSF-1 reformulated eye drops. Potential sellers include ophthalmology distributors, clinic networks, and eye care centers seeking innovative presbyopia therapies and adjunct products to enhance patient outcomes.